Loading…
Psyence Biomedical Ltd. is projected to rise to $6.68 by 2027, a +55% move from its current price of $4.32. PBM is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.96 | $4.32 | $4.72 | +0.09% |
| May 30 | $3.82 | $4.33 | $4.90 | +0.18% |
| May 31 | $3.72 | $4.33 | $5.04 | +0.27% |
| Jun 1 | $3.64 | $4.34 | $5.17 | +0.36% |
| Jun 2 | $3.57 | $4.34 | $5.28 | +0.45% |
| Jun 3 | $3.50 | $4.34 | $5.38 | +0.54% |
| Jun 4 | $3.45 | $4.35 | $5.48 | +0.63% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.45 | $4.35 | $5.48 | +0.63% |
| Week 2 | $3.15 | $4.37 | $6.07 | +1.26% |
| Week 3 | $2.95 | $4.40 | $6.58 | +1.89% |
| Week 4 | $2.79 | $4.43 | $7.04 | +2.53% |
| Week 5 | $2.65 | $4.46 | $7.48 | +3.17% |
| Week 6 | $2.54 | $4.48 | $7.91 | +3.82% |
| Week 7 | $2.44 | $4.51 | $8.33 | +4.47% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Psyence Biomedical Ltd. is a healthcare company focused on the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context.
Its lead product candidate is PEX010, which is in Phase IIb, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer.
The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
PBM is a healthcare stock led by Psyence Biomedical Ltd., currently trading at $4.10 with a market capitalization of $9.4M and ranked 5167 by market cap.
The forecast implies a multi-year price trajectory, with average prices evolving from $4.10 in 2026 to $13.64 in 2050, and maximum projections reaching $31.36 in 2050. The year-by-year averages and maxes outline a generally bullish path in later years, with 2026 showing a neutral stance before rising in subsequent years.
A major floor 48.4% below — a decisive break under it would weaken the trend.
The nearest floor, 33.3% below — buyers have tended to step in here.
The nearest ceiling, 161.6% above — a clean break opens room to run.
A major ceiling 505.8% above — clearing it would confirm fresh momentum.
Key PBM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PBM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.20 | Buy | $4.32 | Sell |
| MA 10 | $4.46 | Sell | $4.55 | Sell |
| MA 20 | $5.19 | Sell | $4.93 | Sell |
| MA 50 | $4.62 | Sell | $6.31 | Sell |
| MA 100 | $6.78 | Sell | $24.29 | Sell |
| MA 200 | $56.76 | Sell | $959.63 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.36 | Neutral |
| Stoch RSI (14) | 34.52 | Neutral |
| CCI (20) | -78.50 | Neutral |
| Williams %R (14) | -80.57 | Info |
| MACD (12,26,9) | -0.19 | Sell |
| ROC (12) | -22.72 | Sell |
| Bollinger %B (20,2) | 0.25 | Neutral |
| Stochastic %K (14) | 19.43 | Buy |
| TRIX (15) | -0.27 | Sell |
| Awesome (5,34) | -1.43 | Sell |
| Ultimate (7,14,28) | 33.29 | Neutral |
| Momentum (10) | -1.25 | Sell |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 4.19 | Buy |
| ADX (14) | 17.85 | Neutral |
| ATR (14) | 0.41 | Info |
The 30-day technical picture is bearish at the moment.
RSI(14) is 40, indicating modest negative momentum. The 50-day simple moving average (SMA) is $4.54, while the 200-day SMA is $58.32. The stock shows a defined support at $2.79 and a resistance at $11.30. The 30-day price range spans from $2.26 to $7.44, reflecting notable near-term volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.23 | $4.32 | $7.69 | 0% | Neutral | |
| $4.80 | $6.68 | $10.04 | +55% | Bullish | |
| $5.01 | $7.38 | $11.80 | +71% | Bullish | |
| $4.02 | $6.24 | $10.45 | +44% | Bullish | |
| $3.78 | $6.15 | $10.73 | +42% | Bullish | |
| $3.59 | $6.10 | $11.00 | +41% | Bullish | |
| $3.01 | $5.34 | $9.93 | +24% | Bullish | |
| $4.58 | $8.45 | $16.13 | +96% | Bullish | |
| $4.98 | $9.55 | $18.70 | +121% | Bullish | |
| $3.90 | $7.78 | $15.58 | +80% | Bullish | |
| $5.06 | $11.24 | $24.71 | +160% | Bullish | |
| $6.43 | $14.30 | $32.88 | +231% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.23 | $4.32 | $5.10 | +0.00% |
| June 2026 | $3.71 | $4.45 | $5.53 | +3.05% |
| July 2026 | $3.84 | $4.69 | $5.97 | +5.27% |
| August 2026 | $3.65 | $4.51 | $5.86 | -3.74% |
| September 2026 | $3.75 | $4.69 | $6.19 | +3.99% |
| October 2026 | $4.27 | $5.40 | $7.22 | +15.05% |
| November 2026 | $4.46 | $5.69 | $7.70 | +5.35% |
| December 2026 | $4.37 | $5.61 | $7.69 | -1.30% |
Click any year to see its month-by-month PBM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, PBM could reach as high as $7.69, with a base case around $4.32 and support toward $2.23 — roughly 0% from $4.32. Price action looks broadly range-bound.
Expect PBM to range from $4.80 to $10.04 through 2027. The $6.68 average target implies a +55% move from current prices. That is up +55% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The PBM price prediction for 2028 points to an average of $7.38 (low $5.01, high $11.80) — a potential gain of +71% on today's $4.32. Momentum favours further upside here.
In 2029, PBM is projected to trade between $4.02 and $10.45, averaging $6.24 — a potential gain of +44% from today's $4.32. That is -16% versus the projected 2028 average. Buyers look set to stay in control over this stretch.
Psyence Biomedical Ltd.'s 2030 outlook centres on $6.15, within a $3.78 to $10.73 range. That is -1% versus the projected 2029 average. That marks a +42% change versus current levels. Momentum favours further upside here.
By 2031, PBM could reach as high as $11.00, with a base case around $6.10 and support toward $3.59 — roughly +41% from $4.32. Buyers look set to stay in control over this stretch.
Expect PBM to range from $3.01 to $9.93 through 2032. The $5.34 average target implies a +24% move from current prices. That is -12% versus the projected 2031 average. Momentum favours further upside here.
The PBM price prediction for 2033 points to an average of $8.45 (low $4.58, high $16.13) — a potential gain of +96% on today's $4.32. Buyers look set to stay in control over this stretch.
In 2034, PBM is projected to trade between $4.98 and $18.70, averaging $9.55 — a potential gain of +121% from today's $4.32. That is up +13% on the projected 2033 average. Momentum favours further upside here.
Psyence Biomedical Ltd.'s 2035 outlook centres on $7.78, within a $3.90 to $15.58 range. That is -19% versus the projected 2034 average. That marks a +80% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, PBM could reach as high as $24.71, with a base case around $11.24 and support toward $5.06 — roughly +160% from $4.32. Momentum favours further upside here.
Expect PBM to range from $6.43 to $32.88 through 2050. The $14.30 average target implies a +231% move from current prices. That is up +27% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in PBM today (≈ 231.481481 PBM) could be worth
$3,309.63
+$2,309.63 (+231%) by 2050 · US Dollar
Based on the average projected PBM price of $14.3 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PBMwould be worth at today's price.
$1,000 invested in PBM on May 27, 2025 (≈ 5.614035 PBM) would be worth
$24.25
-$975.75 (-97.6%) today · 0.02× · US Dollar
Based on a PBM entry price of $178.13 vs. today's $4.32.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.01 | $1,077.31 | +7.7% |
| 1 month ago | $7.05 | $612.77 | -38.7% |
| 3 months ago | $2.62 | $1,648.86 | +64.9% |
| 6 months ago | $59.96 | $72.05 | -92.8% |
| 1 year ago | $178.13 | $24.25 | -97.6% |
| All time (4.5y) ago | $232,031.25 | $0.02 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PBM forecast.
Our base-case forecast reaches $8.60 around 2034.
Implied market cap at $8.60: $19.72M
Multi-year forecasts show a path of evolving values and returns. The 2026 average price is $4.10, rising in later years to $5.88 in 2030 and $13.64 in 2050, with a corresponding max of $31.36 in 2050. The longest-run outlook includes a bullish sentiment from 2027 onward, with annual ROI figures such as 55.7% in 2027, 69.5% in 2028, 44.9% in 2029, 43.5% in 2030, 39.4% in 2031, 24.1% in 2032, 98.1% in 2033, 120% in 2034, 78.7% in 2035, 158.4% in 2040, and 232.6% in 2050.
The forecast portrays a bullish lens for many years, though actual results may vary. These figures are estimates and not guarantees of future performance.
Tap a question to reveal the answer.
The forecast indicates an average price of $5.88 in 2030, with a low of $3.61 and a high of $10.26, and an approximate ROI of 43.5%.
The outlook shows a neutral stance in 2026 and bullish sentiment from 2027 onward, with rising average prices and positive ROI values (e.g., 55.7% in 2027, 232.6% in 2050), though these are estimates.
Yes. The max forecast price reaches $31.36 in 2050.
Current price is $4.10 and market cap is $9.4M.
The 30-day range is from $2.26 to $7.44.
Psyence Biomedical Ltd. Community Discussion
0Share your Psyence Biomedical Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.